Analysts See $-0.07 EPS for Organovo Holdings, Inc. (ONVO) on June, 6

May 17, 2018 - By Pearl Odom

Organovo Holdings, Inc. (NASDAQ:ONVO) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 0.67. That’s change of 0.86, from 2017Q3’s 1.53. 16 investors sold all, 38 reduced holdings as Organovo Holdings, Inc. ratio fall. 18 increased holdings while 18 funds acquired holdings. Funds hold 20.74 million shares thus 13.74% less from 2017Q3’s 24.05 million shares.
Renaissance Techs Ltd Liability Corporation has invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Goldman Sachs owns 181,581 shs. Amer Money Mgmt Lc accumulated 14,900 shs. Morgan Stanley reported 264,614 shs. Ameriprise Financial Incorporated accumulated 142,737 shs or 0% of the stock. Tortoise Investment Management Ltd Liability Co holds 360 shs or 0% of its capital. Private Advisor Group Inc Llc holds 0% in Organovo Holdings, Inc. (NASDAQ:ONVO) or 21,375 shs. The Pennsylvania-based Vanguard Inc has invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Focused Wealth Mngmt reported 2,000 shs. Sei Invs Comm invested in 0% or 8,092 shs. Lmr Prtn Llp has invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). New York-based Blackrock has invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Regions invested in 2,000 shs. Penbrook Mngmt Limited Liability Corp owns 0.33% invested in Organovo Holdings, Inc. (NASDAQ:ONVO) for 269,725 shs. Deutsche Bancshares Ag reported 253,790 shs.

On June, 6. Investors expect Organovo Holdings, Inc. (NASDAQ:ONVO) to publish its quarterly earnings, Zacks reports. earnings per share of $-0.07 is 30.00 % up from 2017’s $-0.1 EPS. 0.00 % EPS growth is what analysts predict. $-0.07 earnings per share was published for last quarter. ONVO is touching $1.7 during the last trading session, after decreased 2.30%.Organovo Holdings, Inc. is downtrending after having declined 67.42% since May 17, 2017. ONVO has 2.45 million volume or 167.54% up from normal. ONVO underperformed the S&P 500 by 78.97%.

Organovo Holdings, Inc., an early commercial stage company, creates and creates functional and three-dimensional human tissues for use in medical research and therapeutic applications.The firm is valued at $188.42 million. The firm develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners.Currently it has negative earnings. The Company’s 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.

More recent Organovo Holdings, Inc. (NASDAQ:ONVO) news were announced by Globenewswire.com, Nasdaq.com and Globenewswire.com. The first one has “New Research Coverage Highlights Tyson Foods, Windstream, Laredo Petroleum, Idera Pharmaceuticals …” as a title and was announced on May 16, 2018. The next is “Organovo Announces Release Date for Fiscal Fourth-Quarter 2018 Financial Results” on May 14, 2018. And last was announced on May 03, 2018, called “Organovo and Samsara Sciences Partner with New Manufacturing USA Institute”.

Organovo Holdings, Inc. (NASDAQ:ONVO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.